Nanexa AB
🇸🇪Sweden
Clinical Trials
5
Active:0
Completed:3
Trial Phases
2 Phases
Early Phase 1:1
Phase 1:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (80.0%)Early Phase 1
1 (20.0%)Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D
Phase 1
Recruiting
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: NEX-22A, a prolonged release formulation of liraglutide
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Nanexa AB
- Target Recruit Count
- 12
- Registration Number
- NCT06439056
- Locations
- 🇩🇪
Profil, Neuss, Germany
To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Nanexa AB
- Target Recruit Count
- 9
- Registration Number
- NCT05643248
- Locations
- 🇸🇪
CTC Clinical Research Consultants AB, Uppsala, Sweden
Pharmacokinetics, Tolerability and Safety of NEX-18a
Phase 1
Completed
- Conditions
- Myelodysplastic Syndromes (MDS)Chronic Myelomonocytic Leukemia (CMML)Acute Myeloid Leukemia (AML)
- Interventions
- Drug: NEX-18a injection
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Nanexa AB
- Target Recruit Count
- 2
- Registration Number
- NCT05048498
- Locations
- 🇸🇪
Karolinska University Hospital Huddinge, Huddinge, Sweden
🇸🇪Kliniska Forsknings och Utvecklings Enheten KFUE, Uppsala, Sweden
News
No news found